Lilly Wins EU Thumbs Up For Kisunla After EMA Reverses Rejection

 
• By Neena Brizmohun
  
U-Turn Sign
The EMA has reversed a negative opinion for Eli Lilly's Alzheimer's drug Kisunla (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from EU CHMP

More from Cell & Gene Therapies